Levi & Korsinsky notifies investors that it has commenced an investigation into Alvotech (NASDAQ: ALVO) concerning potential violations of the federal securities laws.
On November 2, 2025, Alvotech published a press release notifying investors that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) for ATV05. The CRL noted that certain deficiencies must be resolved before the BLA for ATV05 can be approved. Alvotech had submitted a Corrective and Preventive Action (CAPA) plan to the FDA following a previous inspection of the Company’s facility. Management stated that Alvotech is “disappointed” in receiving the CRL. Following this news, Alvotech’s stock price fell over 34.2% to close at $5.03 per share on November 3, 2025.
If you suffered a loss on your Alvotech securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





